Back

Melanonychia and use of nail biopsy to screen for subungual melanoma in a large ethnically diverse pediatric cohort: A cross-sectional study

Park, H. H.; Lieu, A.; Conic, R. R. Z.; Metterle, L.; Zhang, S.; Toledo, I.; Hightower, G. K.

2022-08-12 dermatology
10.1101/2022.08.11.22278683 medRxiv
Show abstract

BackgroundThere are no widely accepted pediatric guidelines on who should undergo biopsy of the nail apparatus to screen for subungual melanoma (SUM). Reported cases of pre-adolescent children diagnosed with SUM presenting as melanonychia remain controversial. Further, observed age differences in the incidence of acral lentiginous melanoma are complicated by reported ethnic differences in adult prevalence and survival rates. MethodsWe conducted a retrospective chart review of Rady Childrens Hospital San Diego, a tertiary hospital system, with over 2 million patients in its electronic health records to identify patients diagnosed with melanonychia younger than 12 years and biopsies in these children, between January 1, 2010, and July 31, 2021. ResultsThere were 623,805 patients younger than 12 years of age seen in the outpatient setting. Average age was 7.2 years for melanonychia diagnosis, and 5.1 years for those biopsied. Nail apparatus biopsies were performed in 22 different individuals and involved the hand 17/22 (77%) and the foot 5/22 (23%). The presence of Hutchinsons sign was documented in 9/22 (41%) patients. Males were diagnosed with melanonychia and underwent biopsy more often than females. Many of the biopsies were performed in Hispanic/Latino 11/22 (50%) and Asian/Pacific Islander 3/22 (14%) patients. DiscussionRegardless of reported ethnicity, biopsy of nail apparatus is highly unlikely to uncover invasive ALM in children younger than 12 years. Prospective studies are needed to understand how incidence of melanonychia, age, gender, and ethnicity/race influence parental and clinicians perceptions of melanoma risk.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Experimental Dermatology
10 papers in training set
Top 0.1%
33.8%
2
Cureus
67 papers in training set
Top 0.5%
6.5%
3
Frontiers in Medicine
113 papers in training set
Top 0.8%
5.0%
4
Journal of Investigative Dermatology
42 papers in training set
Top 0.1%
5.0%
50% of probability mass above
5
PLOS ONE
4510 papers in training set
Top 30%
5.0%
6
JAMA Network Open
127 papers in training set
Top 0.6%
4.4%
7
PLOS Medicine
98 papers in training set
Top 0.8%
4.3%
8
BMC Cancer
52 papers in training set
Top 0.5%
3.8%
9
eClinicalMedicine
55 papers in training set
Top 0.1%
3.1%
10
European Journal of Cancer
10 papers in training set
Top 0.1%
2.9%
11
Scientific Reports
3102 papers in training set
Top 52%
1.9%
12
Pigment Cell & Melanoma Research
11 papers in training set
Top 0.1%
1.8%
13
Cancers
200 papers in training set
Top 3%
1.7%
14
PLOS Neglected Tropical Diseases
378 papers in training set
Top 3%
1.7%
15
Blood Advances
54 papers in training set
Top 0.8%
1.5%
16
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.4%
1.5%
17
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.4%
1.5%
18
Journal of Clinical Pathology
12 papers in training set
Top 0.2%
1.4%
19
Eye
11 papers in training set
Top 0.3%
1.4%
20
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.7%
1.4%
21
Tropical Medicine and Infectious Disease
12 papers in training set
Top 0.2%
1.3%
22
JCI Insight
241 papers in training set
Top 6%
0.9%
23
Nature Communications
4913 papers in training set
Top 59%
0.9%
24
Frontiers in Public Health
140 papers in training set
Top 9%
0.5%
25
Human Genomics
21 papers in training set
Top 0.6%
0.5%